Home Cart Sign in  
Chemical Structure| 19879-32-4 Chemical Structure| 19879-32-4

Structure of Bavachin
CAS No.: 19879-32-4

Chemical Structure| 19879-32-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bavachin, a flavonoid phytoestrogen, can activate the estrogen receptors ERα (EC50 = 320 nM) and ERβ (EC50 = 680 nM).

Synonyms: Corylifolin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bavachin

CAS No. :19879-32-4
Formula : C20H20O4
M.W : 324.37
SMILES Code : C/C(C)=C\CC1=CC(C(C[C@@](O2)([H])C3=CC=C(O)C=C3)=O)=C2C=C1O
Synonyms :
Corylifolin
MDL No. :MFCD11617359
InChI Key :OAUREGNZECGNQS-IBGZPJMESA-N
Pubchem ID :14236566

Safety of Bavachin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7 cells 20 μM 24 h Significantly suppressed PA/OA or high glucose/high insulin-induced increases in the expression of fatty acid synthesis-related genes and the number and size of lipid droplets. Furthermore, bavachin treatment markedly elevated the phosphorylation levels of AKT and GSK-3β, improving the insulin signaling activity in the cells. Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428
human renal tubular epithelial HK-2 cells 0.1 μg/mL 1 h To investigate the effect of Bavachin on LPS-induced expression of kidney injury markers NGAL and KIM-1. Results showed that Bavachin pretreatment significantly inhibited the LPS-induced increase in NGAL and KIM-1 expression. Antioxidants (Basel). 2022 Oct 24;11(11):2096

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice HFD-induced obese mice model Intraperitoneal injection 30 mg/kg Every other day for 8 weeks Efficiently attenuated the increases in body weight, liver weight, blood glucose, and liver and serum triglyceride contents. Moreover, bavachin administration significantly alleviated hepatic inflammation and ameliorated HFD-induced glucose intolerance and insulin resistance. We demonstrated that bavachin protected against HFD-induced obesity by inducing fat thermogenesis and browning subcutaneous white adipose tissue (subWAT). Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428
Mice DEX-induced muscle atrophy model and db/db diabetic mice model Oral 10 mg/kg Once daily for 12 days (DEX model) or 40 days (db/db model) Bavachin enhanced muscle strength and muscle mass, suppressed inflammatory cytokine expression, and improved mitochondrial quality control Antioxidants (Basel). 2023 Jan 6;12(1):137
C57BL/6 mice LPS-induced acute kidney injury (AKI) model Oral 10 and 20 mg/kg Once daily for seven days To evaluate the protective effect of Bavachin on LPS-induced acute kidney injury. Results showed that Bavachin pretreatment significantly inhibited the increase in serum creatinine and blood urea nitrogen levels, improved kidney injury scores, and reduced the expression of tubular injury markers NGAL and KIM-1. Antioxidants (Basel). 2022 Oct 24;11(11):2096

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.08mL

0.62mL

0.31mL

15.41mL

3.08mL

1.54mL

30.83mL

6.17mL

3.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories